Log in

NASDAQ:DERM - Dermira Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 02/20/2020)
Today's Range
Now: $18.75
50-Day Range
MA: $18.75
52-Week Range
Now: $18.75
Average Volume1.24 million shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Read More
Dermira logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:DERM



Sales & Book Value

Annual Sales$42.34 million
Book Value($0.21) per share


Net Income$-221,540,000.00
Net Margins-256.08%


Market Cap$1.02 billion
Next Earnings DateN/A

Receive DERM News and Ratings via Email

Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.

Dermira (NASDAQ:DERM) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Dermira?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dermira.

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.40) by $0.34. The biopharmaceutical company earned $11.53 million during the quarter, compared to analyst estimates of $11.07 million. Dermira had a negative net margin of 256.08% and a negative return on equity of 583.07%. View Dermira's earnings history.

What price target have analysts set for DERM?

7 Wall Street analysts have issued 12-month price targets for Dermira's shares. Their forecasts range from $14.00 to $25.00. On average, they expect Dermira's stock price to reach $18.55 in the next twelve months. This suggests that the stock has a possible downside of 1.1%. View analysts' price targets for Dermira.

What are Wall Street analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:
  • 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $7 price target. The STING program currently contributes approximately 53% to our valuation (no contribution from early stage Lilly program currently) and the APRIL program approximately 43%, with the remainder coming from the anti-CD27 program being developed by Merck (MRK; not rated). Our target is based on our clinical net present value (NPV) model. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (5/8/2019)
  • 3. Cantor Fitzgerald analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (5/3/2019)

Has Dermira been receiving favorable news coverage?

Media headlines about DERM stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dermira earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutDermira.

Who are some of Dermira's key competitors?

What other stocks do shareholders of Dermira own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), AT&T (T), Novavax (NVAX), Exelixis (EXEL), Bristol-Myers Squibb (BMY), ImmunoGen (IMGN), Karyopharm Therapeutics (KPTI) and Sangamo Therapeutics (SGMO).

Who are Dermira's key executives?

Dermira's management team includes the following people:
  • Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 67)
  • Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 77)
  • Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 51)
  • Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 42)
  • Mr. Christopher M. Griffith, Co-Founder and Chief Bus. & Strategy Officer (Age 43)

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

Who are Dermira's major shareholders?

Dermira's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Fred Alger Management LLC (5.60%), Oracle Investment Management Inc. (4.64%), Bank of America Corp DE (3.70%), State Street Corp (1.80%), Broadfin Capital LLC (1.64%) and Earnest Partners LLC (1.48%). Company insiders that own Dermira stock include Eagle Acquisition Corp Bald, Eugene A Bauer, Matthew K Fust and Thomas G Wiggans. View institutional ownership trends for Dermira.

Which institutional investors are selling Dermira stock?

DERM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Credit Suisse AG, Citigroup Inc., Fred Alger Management LLC, Renaissance Technologies LLC, Sofinnova Investments Inc., Panagora Asset Management Inc., and Partner Investment Management L.P.. Company insiders that have sold Dermira company stock in the last year include Eugene A Bauer, and Matthew K Fust. View insider buying and selling activity for Dermira.

Which institutional investors are buying Dermira stock?

DERM stock was bought by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Jacobs Levy Equity Management Inc., Broadfin Capital LLC, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Earnest Partners LLC, Alliancebernstein L.P., and EAM Global Investors LLC. Company insiders that have bought Dermira stock in the last two years include Eagle Acquisition Corp Bald, and Thomas G Wiggans. View insider buying and selling activity for Dermira.

What is Dermira's stock price today?

One share of DERM stock can currently be purchased for approximately $18.75.

How big of a company is Dermira?

Dermira has a market capitalization of $1.02 billion and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis. Dermira employs 333 workers across the globe. View additional information about Dermira.

What is Dermira's official website?

The official website for Dermira is http://www.dermira.com/.

How can I contact Dermira?

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]

MarketBeat Community Rating for Dermira (NASDAQ DERM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  341 (Vote Outperform)
Underperform Votes:  309 (Vote Underperform)
Total Votes:  650
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel